News

The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. Additionally, the whole genome sequencing (WGS) capabilities of

This decision was issued in a Complete Response Letter (CRL) which cited deficiencies at a third-party manufacturing facility producing OLC. The FDA did not raise concerns related to

Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios

The MOIP has issued Patent Number 10-2960889, providing protection for Anixa’s breast cancer vaccine approach in South Korea through 2040. This specific composition-of-matter patent is exclusively licensed from

Under the terms of the deal, Theravance Biopharma shareholders will receive $17 per share. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of

The FDA has requested further information, primarily focusing on the manufacturing control strategy of the biological component of NASP and on deficiencies related to contract manufacturing facilities. It

This Jaypirca CHMP recommendation for CLL applies across all lines of therapy, regardless of previous Bruton tyrosine kinase (BTK) inhibitor treatment. Following this recommendation, the Jaypirca application moves

Ionis will retain the responsibility for commercialising the RNA-targeted medicine within the US and will remain the global lead for development activities. Under the agreement, Recordati will handle regulatory

The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. It makes the combination the first regimen that pairs a programmed death-1 (PD-1)